Verified PCD pharma franchise companiesThird party pharma manufacturersTablets · Capsules · Syrups · InjectionsBaddi · Haridwar · Ahmedabad · SikkimLow MOQ for new brandsFree quotes within 24 hoursList your company free
Third Party Manufacturing

Third Party Pharma Manufacturing in 2026: What Revised Schedule M and UCPMP 2024 Mean for Brand Owners

Revised Schedule M, UCPMP 2024 and stricter batch testing have changed how brand owners should choose and work with third-party pharma manufacturers. A practical 2026 guide with checklists and FAQs.

15 min read
Third Party Pharma Manufacturing in 2026: What Revised Schedule M and UCPMP 2024 Mean for Brand Owners
In this article 14 sections
  1. A Quick Refresher: How Third-Party Manufacturing Works
  2. Revised Schedule M: What Actually Changed
  3. What Revised Schedule M Means for Brand Owners
  4. The Raw Material Testing Push After 2025
  5. UCPMP 2024: The Marketing Side of the Story
  6. How to Choose a Third-Party Manufacturer in 2026
  7. A Brand Owner's Compliance Checklist
  8. Speciality Ranges and Third-Party Manufacturing: Where the New Rules B...
  9. Opportunities Hidden in the New Rules
  10. Common Mistakes Brand Owners Make Right Now
  11. Questions to Ask Your Franchise Company About Outsourced Products
  12. Cost Planning for Your Own Brand in 2026
  13. Frequently Asked Questions
  14. Get Your Brand Made With a Compliant Manufacturer

For years, getting your own pharma brand made was mostly about three things: a good rate, a decent minimum order and a plant that dispatched on time. That world has changed. In 2026, the plant behind your brand carries far more weight than it used to, and so does the way you market the product once it leaves the factory.

Two sets of rules have reshaped third-party pharma manufacturing in India. The first is Revised Schedule M, the upgraded Good Manufacturing Practice standard that became binding on every manufacturing unit from 1 January 2026. The second is the Uniform Code for Pharmaceutical Marketing Practices 2024, which governs how companies promote medicines to doctors. On top of these, the drug regulator has pushed hard on batch-wise testing of raw materials since the cough syrup tragedy of 2025.

If you own a brand, plan to launch one, or buy from a PCD pharma franchise company that outsources its production, this guide explains what the new rules mean for you in plain language, and what you should change in the way you choose and work with a manufacturer.

A Quick Refresher: How Third-Party Manufacturing Works

In third-party manufacturing, also called contract manufacturing, a licensed plant produces medicines that are sold under someone else's brand name. The brand owner, usually a marketing company or a distributor, decides the product list, the brand names and the packaging design. The manufacturer holds the drug manufacturing licence and is responsible for making the product correctly, testing it and releasing each batch.

The model is popular because it lets a marketing company build a brand without spending crores on a factory. A new company can launch fifty products by working with three or four specialist plants, each strong in a particular dosage form. Apromart lists these manufacturers by form, from tablets and capsules to syrups, injections and softgels.

The catch is that the brand owner's reputation depends entirely on someone else's factory. If a batch fails, it is your brand name in the drug alert, not the plant's. That is why the 2026 rule changes matter so much to brand owners.

Revised Schedule M: What Actually Changed

Schedule M is the part of the Drugs Rules, 1945 that sets out Good Manufacturing Practice for pharmaceutical plants. The revised version was notified in December 2023 to bring Indian standards closer to the World Health Organization's GMP approach. Large manufacturers had to comply first. Micro, small and medium units were given more time, and the government formally extended their deadline to 31 December 2025. From 1 January 2026, the revised rules apply to everyone, and regulators have started risk-based inspections.

The revised rules are long and technical, but the main shifts are easy to follow:

  • A real pharmaceutical quality system. Plants must run a documented quality system with management oversight, rather than relying on a few checks at the end of production.
  • Quality risk management. Manufacturers are expected to identify risks in their processes and control them before something goes wrong.
  • Product quality reviews. Each product's batches must be reviewed regularly to spot trends, failures and complaints.
  • Equipment and process validation. Machines, utilities and processes must be qualified and validated, with records to prove it.
  • Stability programmes. Products must be tested over time to show they remain within specification until expiry.
  • Supplier qualification. Vendors of APIs, excipients and packing materials must be qualified and audited.
  • Computerised systems and data integrity. Electronic records must be secure, traceable and protected from tampering.
  • Stronger rules for sterile products. Injectables and eye drops face tighter cleanroom, environmental monitoring and validation demands.

For a well-run plant, much of this was already in place. For many smaller units, it meant real investment in new equipment, extra quality staff and better documentation. Some units have upgraded fully, some are still catching up, and a few have stopped production. Business Standard and other business papers have tracked how MSME units struggled with the cost of the upgrade through 2025.

What Revised Schedule M Means for Brand Owners

You do not run the factory, so why should you care? Because the rules change what you can expect from your manufacturer, what you should ask for, and how much you will pay.

Your supplier list may change

If one of your plants has not upgraded, it may face inspection findings, suspension or cancellation of its licence. That can leave you suddenly without stock. Many brand owners spent 2025 quietly moving products to upgraded plants. If you have not checked the status of every plant that makes your products, do it now.

Rates have gone up in many cases

Upgrades cost money, and some of that cost is passed on. Expect purchase rates from compliant plants to be slightly higher than what you paid in 2023 or 2024, especially for liquids and sterile products. Be cautious of a plant that still quotes old rates without any explanation. It may be cutting corners.

Documentation will be better, and you should use it

Compliant plants now have stability data, product quality reviews, validated processes and qualified vendors on file. Ask to see summaries. These documents are your protection if a regulator or a doctor ever questions your product.

Lead times may stretch

More testing and more documentation take time. Liquids in particular now need batch-wise excipient testing and DEG and EG checks before release. Build an extra week or two into your planning, especially before peak seasons.

Minimum orders may rise

Validated processes often work best at fixed batch sizes. Some plants have raised their minimum batch to make each validated run economical. Negotiate, but understand why.

The Raw Material Testing Push After 2025

Revised Schedule M would have been enough on its own, but 2025 added another layer. After children died from contaminated cough syrup, the Drugs Controller General of India reminded every state that manufacturers must test each batch of active and inactive ingredients before use, as already required by the Drugs Rules. Medical Dialogues reported that inspections had found manufacturers skipping these tests. In October 2026, the regulator again asked states to enforce raw material testing and vendor qualification, naming propylene glycol, glycerol and sorbitol as critical excipients.

For a brand owner, this is a clear signal. You must know that your manufacturer tests every lot of raw material and every finished batch, and you should be able to get a certificate of analysis for each batch you buy. If your plant hesitates to share this, that tells you something.

UCPMP 2024: The Marketing Side of the Story

Manufacturing is only half your business. The other half is how you promote your brands. On 12 March 2024, the Department of Pharmaceuticals notified the Uniform Code for Pharmaceutical Marketing Practices 2024. It applies to pharmaceutical companies and sets limits on how they deal with healthcare professionals.

The key points brand owners need to know:

  • No gifts or personal benefits to doctors or their family members, beyond very limited exceptions.
  • No sponsored travel or hospitality for doctors to attend conferences or holidays, except in narrowly defined situations such as speaking engagements.
  • Free samples are restricted in quantity and must be properly recorded, and they cannot be given to people not qualified to prescribe.
  • Claims must be accurate. Promotional material must be balanced, supported by evidence and consistent with the approved use of the product. Words like "safe" or "new" need justification.
  • Continuing medical education events must follow transparent guidelines, with spending details disclosed.
  • Ethics committees. Companies are expected to set up an Ethics Committee for Pharma Marketing Practices to handle complaints, and the chief executive must file an annual self-declaration of compliance.

For a small brand owner, the practical message is this: do not build your sales plan on gifts and trips. Build it on reliable products, good literature, honest claims and consistent visits by trained representatives.

How to Choose a Third-Party Manufacturer in 2026

With all of this in mind, here is a practical way to shortlist and select a manufacturer today. It takes longer than a phone call and a rate list, but it will save you from very expensive mistakes.

1. Start with the right dosage specialist

Decide which forms you need and look for plants that specialise in them. A plant brilliant at tablets may be average at syrups. Apromart's listings for ointments and creams, derma cosmetics, ayurvedic products, nutraceuticals and veterinary medicines make this comparison easier.

2. Ask for the Schedule M status in writing

Ask the plant to confirm whether it has completed the Revised Schedule M upgrade, when it was last inspected, and whether any observations are pending. A confident manufacturer will share this freely.

3. Check licences and certificates

Ask for the drug manufacturing licence with the list of approved products, the WHO-GMP certificate if they hold one, and any ISO certificates. Check that the products you want are endorsed on their licence.

4. Look at the quality control lab

A good plant has a well-equipped in-house lab with HPLC, dissolution apparatus, stability chambers and, for liquids, the gas chromatography setup needed for DEG and EG testing. If the plant outsources most testing, ask which approved lab it uses.

5. Review sample documents

Ask for a sample certificate of analysis, a batch manufacturing record with confidential details hidden, and a stability summary for one of your intended products.

6. Visit the plant

Nothing replaces a visit. Look at cleanliness, how materials are labelled and stored, whether staff wear proper gowns, and how the warehouse separates approved and quarantined materials. If you are in the Chandigarh, Panchkula or Mohali area, plants in Baddi are only a short drive away. Haridwar is close for buyers in Uttarakhand and western Uttar Pradesh, and Ahmedabad serves Gujarat and western India.

7. Agree commercial terms clearly

Get rates, minimum batch size, payment terms, lead times, artwork approval process, stability responsibility and liability for failed batches written into your agreement.

8. Start small, then scale

Begin with a few products, check quality and service across two or three batches, then move more products to the plant.

A Brand Owner's Compliance Checklist

Here is a short checklist you can keep on your desk.

  • Every plant that makes your products has completed its Revised Schedule M upgrade.
  • Each product is endorsed on the manufacturer's licence, and no product is a banned fixed-dose combination. The CDSCO website lists banned FDCs and approved new drugs.
  • You receive a certificate of analysis for every batch you buy, and liquid batches show DEG and EG results.
  • Your labels carry all mandatory details, and MRPs for scheduled formulations are within the ceiling published by the NPPA.
  • Your brand names have been checked for trademark conflicts and look-alike names.
  • Your promotional material and sample policy follow UCPMP 2024.
  • You keep purchase invoices, batch records and distribution records for every batch, so you can trace and recall stock quickly if needed.
  • You have a simple complaint-handling process, and you pass quality complaints to the manufacturer promptly.

Speciality Ranges and Third-Party Manufacturing: Where the New Rules Bite Hardest

Not every speciality range is affected equally. Knowing where the pressure is heaviest helps you plan.

Respiratory and paediatric ranges carry the most syrups, so they feel the full weight of the excipient and DEG and EG testing push. Choose liquid manufacturers carefully and keep their batch records on file. See respiratory PCD companies for partners in this area.

Critical care and injectables face the strictest sterile manufacturing requirements. Only plants with proper cleanroom grades, validated sterilisation and strong environmental monitoring should be making your injections. Explore critical care PCD companies.

Ophthalmic ranges are also sterile products and need the same level of care. Check ophthalmic PCD companies.

Cardio-diabetic and neuro ranges rely heavily on sustained-release and bilayer tablets, so dissolution testing and process validation matter most. Browse cardiac and diabetic and neuro-psychiatry partners.

Derma and cosmetic ranges mix drugs and cosmetics, each under different rules. Make sure each product is made under the correct licence. See derma PCD companies.

Ayurvedic and nutraceutical ranges are regulated separately under AYUSH and FSSAI rules, but quality expectations are rising there too. Compare ayurvedic PCD companies and nutraceutical PCD companies.

Opportunities Hidden in the New Rules

It is easy to see the new rules only as extra cost and paperwork. But there is a real upside for brand owners who adapt early.

First, weaker competitors are leaving the market. When a cheap but non-compliant supplier drops out, doctors and chemists who bought from them need a new source. A brand with clean records can step in.

Second, trust has become a selling point. Doctors are more willing to try a new brand if the representative can show a WHO-GMP certificate, a Schedule M compliant plant and batch-wise test reports. Quality documents now open doors that gifts used to open.

Third, export opportunities grow. Plants that meet the revised standard are closer to WHO expectations, which helps brand owners who want to sell in African, Southeast Asian or Latin American markets in future.

Fourth, partnerships become more stable. When you choose a well-run plant and build a long relationship, you get consistent quality, priority in busy seasons and support with new product development.

Common Mistakes Brand Owners Make Right Now

A few errors keep coming up. Some brand owners still pick a plant purely on the lowest rate and discover later that the unit has pending inspection observations. Some assume that if a franchise company is compliant, all its outsourced products must be too, without checking each plant. Others print bold claims on cartons or visual aids that the product's approval does not support, which is risky under UCPMP 2024. And many do not keep batch-wise records of where their stock went, which makes a recall painful and slow.

Each of these is easy to avoid with a little discipline: check every plant, keep every document, and promote honestly.

Questions to Ask Your Franchise Company About Outsourced Products

Many distributors never deal with a plant directly. They buy from a PCD franchise company that sources products from several third-party units. If that describes you, the new rules still matter, because the stock in your godown came from those plants. Before your next order, put these questions to your company:

  • Which plant makes each product on my list, and where is it located?
  • Has each of those plants completed the Revised Schedule M upgrade?
  • Can you share the certificate of analysis for the batches you send me?
  • For syrups and suspensions, are DEG and EG results included in the batch report?
  • How quickly will you inform me if a batch is recalled or flagged in a drug alert?
  • How does your promotional material comply with UCPMP 2024?

A company that answers clearly and quickly is one you can grow with. One that avoids these questions may cause problems later, and it is better to find that out before you commit to a large order. You can compare franchise companies by speciality on the speciality-wise PCD pharma companies page and by form on the dosage-wise PCD pharma companies page.

Cost Planning for Your Own Brand in 2026

Many first-time brand owners underestimate the total cost. Beyond the purchase rate, plan for trademark searches and filings, artwork and packaging design, printing of cartons, labels and leaflets, the first batch at minimum order quantity for each product, freight from the plant, godown space with proper storage, your wholesale drug licence, and promotional material such as visual aids and product cards. A realistic launch with 20 to 30 products from two or three plants often needs anywhere between Rs 8 lakh and Rs 25 lakh, depending on dosage forms and batch sizes. Liquids and softgels usually push the number up, while plain tablets keep it lower.

Keep a reserve for re-orders. The first few months are when doctors start writing your products, and running out of stock at that moment does real damage.

Frequently Asked Questions

What is Revised Schedule M?

It is the upgraded Good Manufacturing Practice standard under the Drugs Rules, 1945. It brings Indian plants closer to WHO GMP expectations, with stronger quality systems, risk management, validation, stability programmes and data integrity rules.

From when is Revised Schedule M mandatory for all manufacturers?

Large manufacturers had to comply first. The extended deadline for micro, small and medium units ended on 31 December 2025, so from 1 January 2026 it applies to all units.

Does Revised Schedule M apply to brand owners who do not own a plant?

The rules bind the manufacturing licence holder. But as a brand owner, your products and reputation depend on that plant's compliance, so you should check the status of every plant you work with.

What is UCPMP 2024?

The Uniform Code for Pharmaceutical Marketing Practices 2024 was notified by the Department of Pharmaceuticals on 12 March 2024. It sets rules on gifts, travel, samples, promotional claims and medical education events for pharmaceutical companies.

Can I still give samples to doctors?

Yes, but in limited quantities, only to qualified prescribers, and with proper records. Samples must be clearly marked as not for sale.

Why are third-party manufacturing rates higher in 2026?

Plants have invested in upgrades, extra testing, validation and quality staff to meet the revised rules and the raw material testing push. Some of that cost is reflected in rates.

How do I know if a manufacturer tests every batch?

Ask for a certificate of analysis for each batch you buy. For liquids, it should include DEG and EG results. A reliable manufacturer shares these routinely.

Where can I find verified third-party manufacturers?

Apromart lists third-party manufacturers by dosage form and speciality, with filters for major hubs such as Baddi, Haridwar, Ahmedabad and the Chandigarh tri-city. Always verify licences and visit the plant before signing.

Get Your Brand Made With a Compliant Manufacturer

The rules of 2026 reward brand owners who take quality seriously. Pick plants that have upgraded, ask for the documents that prove it, promote your products honestly, and keep clean records. Do that, and the new rules become an advantage rather than a burden.

Start comparing third-party pharma manufacturers, look at contract pharma manufacturing units, or post your requirement and let top companies listed from PAN India reach you. For any help, contact the Apromart team.

Found this useful? Share it
Keep reading

Related articles

All articles →

Latest from the blog

Ready to start your pharma franchise journey?

Post one requirement and get quotes from verified PCD franchise companies and third-party manufacturers — free.

Call +91 98772 38195 WhatsApp Now

Post your requirement

Get quotes from verified pharma companies — free.

I'm looking for
GST number?
Drug licence?
Your number is shared only with matching companies.